New Study Highlights Diabetes Risk Spike in First 90 Days of Antipsychotic Treatment
Research indicates that the initial three months after starting antipsychotic medications are critical for monitoring diabetes risk.
The first 90 days of antipsychotic treatment see a significant rise in blood sugar and weight.
Olanzapine poses the highest diabetes risk among second-generation antipsychotics.
Regular metabolic monitoring is recommended within three months of starting treatment.
A recent study has revealed that the initial 90 days following the prescription of antipsychotic medications is a pivotal period for monitoring the risk of diabetes in patients. Conducted by researchers and published in The Lancet Psychiatry, the study emphasizes the need for heightened vigilance during this timeframe, particularly for individuals diagnosed with severe mental illnesses such as schizophrenia and bipolar disorder.
The research analyzed electronic health records of over 96,000 individuals aged between 18 and 59 who had received at least two prescriptions for one of four second-generation antipsychotics from January 2000 to June 2023. It was found that significant changes in weight and blood sugar levels occurred within the first three months of treatment, with the participants' HbA1c levels rising 14 times faster compared to the two years preceding treatment. Weight gain was also accelerated, occurring approximately nine times faster during this period.
Among the antipsychotics studied, olanzapine was identified as having the most substantial impact on diabetes risk factors. The study noted that HbA1c levels in patients taking olanzapine increased 50 times faster in the first 90 days, while weight gain was observed to be ten times faster than prior to treatment. Furthermore, the study highlighted a gender disparity, with women experiencing a more pronounced increase in both HbA1c and weight compared to men during the same period.
The findings underscore the importance of regular monitoring of blood sugar levels for patients on antipsychotic medications, as recommended by the National Institute for Health and Care Excellence. The researchers advocate for metabolic monitoring to be conducted within three months of initiating antipsychotic treatment, as rapid changes in HbA1c and weight may not always correlate, indicating that monitoring weight alone may not suffice in identifying at-risk patients.
Dr. Juan Carlos Bazo-Alvarez, a researcher from University College London, emphasized the significance of early monitoring, stating that healthcare professionals should assess both weight and blood sugar levels before and during the initial months of treatment. This proactive approach could facilitate early detection of potential health issues, allowing for timely intervention and support, ultimately enabling patients to benefit from antipsychotic medications while minimizing their risk of developing type 2 diabetes.
